Tissue Regenix Grp Live Discussion

Live Discuss Polls Ratings
Page

ybhere 12 Jul 2016

Re: News Morning SP,You make the comment about the NHS 'Look at the NHS tissue deal - what has that really delivered. Tissue Ulcers a chuffing big problem - we allegedly have the solution - so why are the products not flying off the shelves?'TRX was created here in the north east in York but, from a business perspective, despite the outstanding benefits of the TRX technology, which Health Service will invest the fastest and the most and prove the technology? It's the American Health Service where basically the Insurance Company's foot the bill for Health Care and will pile in if they can see a saving on their expenditure. And, by all accounts, the saving is massive. The American Company that manufactures the 'scaffold' (can't remember its name) with Agents covering practically the whole of the USA could possibly set up here in the UK. They must realise the global potential with the NHS and European market waiting to be developed. The NHS wont invest or cant invest the millions required to set up a scaffold manufacturing facility here in the UK. The bean counters and box tickers wont allow it.Another company that has gone down the same route is Advanced Oncotherapy with their Proton Beam technology which is a spin off from the CERN reactor. Remember the child taken by parents out of NHS care to Czechoslovakia for Proton Beam Therapy much to the annoyance of Social Services Services? Their Proton Beam generator is a technology that will be superceded by this new technology, but the NHS didn't even offer that.. The Americans have their orders in and the last time I looked, Harley Street had ordered one. NHS??? [link] my view.YB

swisspaul 12 Jul 2016

Re: News Quite strange - revenue, never considered that as an indicator of success. I thought it was profit? Any fool can sell things - even at a loss - that's revenue?Perchance are you a member of the scientific community or a philanthropist happily subsidising the scientific and salesman community. Me am just a poor investor who wants a decent return on his money - nominally in the shape of dividends but an increase in share price will do for the moment.Oh the guff is relevant as its what your paying for - as we still have a salesforce and other items as mentioned in my previous

swisspaul 12 Jul 2016

Re: News Quite strange - revenue, never considered that as an indicator of success. I thought it was profit? Any fool can sell things - even at a loss - that's revenue?Perchance are you a member of the scientific community or a philanthropist happily subsidising the scientific and salesman community. Me am just a poor investor who wants a decent return on his money - nominally in the shape of dividends but an increase in share price will do for the moment.

theprior 11 Jul 2016

Re: News SPee, don't know about the other board.I'm happy to wait for the next set of figures which will, no doubt, show an increase in revenue.All the guff that's gone before is not relevant to the here and now.Good luck, TP (that's Tee Pee)

swisspaul 11 Jul 2016

Re: News The P - I refer you to another board on which I made the following commenth I well and truly understand - have you? Did your read the annual report and accounts. Can you give me a breakdown of sales by geography? Can you tell me what the remuneration of our US sales force was based against how many sales - taking into consideration the geographical spread of where the insurance cover is?Joe - I was excited when I thought - eh up someone else is getting it. Show me a line in that statement that promises a delivery. Words such as: Positive discussion with FDA Initial clinical evidence (read the book Bad Pharma for interpretation) is now expected to gain a CE mark. The possibility of earlier EU approval for OrthoPure(TM) XT, and the potential for a US pilot study, would allow us to access these key markets via a more rapid regulatory route, where sales momentum can be quickly established, particularly with our 'off the shelf' alternative to the existing approaches. So come on - be honest - what have they really told you - besides building up your expectations - trouble is they have don that considerably in the past. Look at the NHS tissue deal - what has that really delivered. Tissue Ulcers a chuffing big problem - we allegedly have the solution - so why are the products not flying off the shelves? I hold - but am coming to the conclusion that a commercial person needs to take this forward as its all research and possibilities. Look at IQE - same problem - run by boffins and not made a profit in a decade. IOTS

theprior 11 Jul 2016

Re: News Come on Paul, can't you see that this news will drive sales forward. Figures in the annual report will confirm this. Just you wait and see ))TP

waytogo333 11 Jul 2016

Re: News Yes, great to see the 'ducks' starting to line up. Long may it continue.....

swisspaul 11 Jul 2016

Re: News The supposedly good news would be better if it was about sales

theprior 11 Jul 2016

News RNS today.Development and validation of the products continues apace.Good news indeed !!TP

waytogo333 14 Jun 2016

Re: New boy indeed......

swisspaul 09 Jun 2016

Re: New boy Or lack of contracts!IOTS

waytogo333 09 Jun 2016

Re: New boy Been here a while myself and agree this co has massive potential. Taking longer than I originally thought, but expect to see their products being increasingly adopted both in the US and Europe.Technicals suggest we may have a drop before the next push up, but news/contracts drives the sp here.

theprior 03 Jun 2016

Re: New boy Welcome, rig. This is, unfortunately a quiet BB, but the company is far from quiet with lots going on in several areas. (As you will no doubt know from your research)Not a traders share but one which will definitely reward handsomely with patience. A slow steady climber.Good luck, TP

rig mover 03 Jun 2016

New boy That's my 5k this morning. Kind of testing this share but feeling a bit lonely already!

theprior 01 Jun 2016

RNS New non exec Brilliant addition to the board to create clinical expertise alongside the push to commerciality.TP

Page